Mereo Biopharma Group Plc ADR’s recent filing unveils that its Chief Executive Officer Scots-Knight Denise unloaded Company’s shares for reported $0.25 million on Sep 13 ’24. In the deal valued at $4.22 per share,60,046 shares were sold. As a result of this transaction, Scots-Knight Denise now holds 808,921 shares worth roughly $2.11 million.
Then, Scots-Knight Denise sold 28,611 shares, generating $127,968 in total proceeds. Upon selling the shares at $4.47, the Chief Executive Officer now owns 868,967 shares.
Before that, Lewicki John A. sold 10,937 shares. Mereo Biopharma Group Plc ADR shares valued at $46,165 were divested by the Chief Scientific Officer at a price of $4.22 per share. As a result of the transaction, Lewicki John A. now holds 78,630 shares, worth roughly $0.21 million.
JP Morgan initiated its Mereo Biopharma Group Plc ADR [MREO] rating to an Overweight in a research note published on March 27, 2025; the price target was $7. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Robert W. Baird began covering MREO with “an Outperform” recommendation on June 13, 2024.
Price Performance Review of MREO
On Monday, Mereo Biopharma Group Plc ADR [NASDAQ:MREO] saw its stock jump 4.40% to $2.61. Over the last five days, the stock has gained 12.02%. Mereo Biopharma Group Plc ADR shares have fallen nearly -25.43% since the year began. Nevertheless, the stocks have fallen -6.12% over the past one year.
Levels Of Support And Resistance For MREO Stock
The 24-hour chart illustrates a support level at 2.53, which if violated will result in even more drops to 2.44. On the upside, there is a resistance level at 2.67. A further resistance level may holdings at 2.72. The Relative Strength Index (RSI) on the 14-day chart is 61.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 2.83%. Stochastics %K at 94.44% indicates the stock is a selling.
How much short interest is there in Mereo Biopharma Group Plc ADR?
A steep rise in short interest was recorded in Mereo Biopharma Group Plc ADR stocks on 2025-04-15, growing by 0.57 million shares to a total of 6.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 6.03 million shares. There was a rise of 8.64%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 12, 2022 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $4 price target.
